Rexahn pharmaceuticals, inc. (RNN)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
Current Assets:
Cash and cash equivalents

10,998

9,219

7,932

7,310

6,122

8,744

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash and cash equivalents

-

-

-

-

-

-

4,591

5,094

6,298

8,899

8,226

8,790

10,486

11,578

8,392

7,877

10,463

10,199

12,450

9,970

10,729

9,826

14,971

38,104

40,073

18,688

14,871

9,979

12,069

13,486

7,379

8,482

8,101

9,861

13,216

16,127

12,340

Marketable securities

-

2,997

5,981

8,950

11,892

5,981

7,974

11,647

14,884

17,931

14,977

17,986

8,016

8,737

13,419

11,519

14,005

13,240

9,006

16,013

18,655

22,872

20,613

100

100

100

100

100

100

100

100

100

1,950

1,950

1,950

1,950

2,451

Prepaid expenses and other current assets

290

447

722

1,033

976

1,173

1,154

1,365

1,231

1,304

1,277

1,199

965

608

802

996

946

1,221

1,475

1,277

991

730

757

-

-

507

-

-

-

-

-

-

-

-

-

-

-

Research tax credit receivable (note 16)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

145

Prepaid expenses and other current assets (note 4)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

901

725

-

523

390

183

188

218

333

287

333

455

486

706

Note receivable - current portion (note 5)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

11

18

25

28

28

Total Current Assets

11,288

12,663

14,635

17,293

18,992

15,899

13,720

18,107

22,414

28,135

24,481

27,976

19,468

20,924

22,613

20,393

25,414

24,661

22,932

27,261

30,376

33,429

36,343

39,105

40,898

19,295

15,494

10,470

12,352

13,775

7,698

8,921

10,350

12,163

15,648

18,591

15,672

Restricted Cash Equivalents (note 7)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

37

78

163

196

509

568

957

1,091

217

763

1,275

1,431

2,947

3,177

401

Security Deposits

25

25

25

25

30

30

30

30

30

30

30

30

30

30

30

30

30

30

30

30

25

25

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating Lease Right-of-Use Assets

171

203

233

263

303

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Note Receivable (note 6)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

4

18

Equipment, Net

66

75

85

94

99

112

123

97

109

121

79

86

83

88

97

105

111

112

110

77

79

78

72

60

59

65

70

35

43

52

62

73

83

94

93

100

123

Total Assets

11,552

12,968

14,980

17,677

19,425

16,042

13,874

18,235

22,554

28,287

24,590

28,093

19,582

21,043

22,741

20,530

25,557

24,805

23,074

27,369

30,481

33,533

36,453

39,244

41,121

19,556

16,073

11,074

13,352

14,919

7,977

9,758

11,709

13,689

18,688

21,875

16,216

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable and accrued expenses

1,237

1,265

1,366

1,920

2,246

3,152

3,331

3,381

3,049

3,233

2,338

1,917

1,715

1,882

1,785

1,794

3,284

2,661

3,238

3,168

2,749

2,459

1,725

1,539

878

933

750

620

976

851

871

890

1,020

1,185

3,905

3,891

1,820

Deferred revenue

600

1,500

1,500

1,500

150

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities, current

144

139

135

130

113

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total Current Liabilities

1,981

2,905

3,001

3,551

2,509

3,152

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating Lease Liabilities, non-current

25

63

100

136

181

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant Liabilities

100

41

123

366

794

2,307

4,101

3,391

4,487

7,853

6,676

9,796

16,233

1,573

3,161

2,340

4,459

2,739

1,476

2,094

3,652

3,768

5,382

6,583

11,290

5,034

4,192

3,662

2,473

2,842

1,524

328

1,130

868

3,653

5,519

2,966

Deferred Research and Development Arrangement

-

-

-

-

-

-

-

-

-

375

393

412

431

450

468

487

506

525

543

562

581

600

618

678

782

833

1,165

1,243

1,472

1,626

768

787

806

825

843

-

900

Deferred Revenue (note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

862

-

Other Liabilities

-

-

-

-

-

19

29

39

48

56

61

65

72

79

85

92

98

104

109

115

120

124

129

134

138

129

114

44

55

65

75

85

95

104

113

122

133

Total Liabilities

2,107

3,010

3,225

4,054

3,485

5,480

7,463

6,812

7,584

11,519

9,470

12,192

18,453

3,985

5,501

4,715

8,347

6,029

5,368

5,940

7,103

6,952

7,855

8,935

13,089

6,931

6,222

5,571

4,977

5,385

3,240

2,092

3,051

2,983

8,516

10,396

5,820

Commitments and Contingencies (note 11)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Stockholders' Equity:
Preferred stock, par value $0.0001, 10,000,000 authorized shares, none issued and outstanding

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

0

0

0

0

0

Common stock, par value $0.0001, 75,000,000 authorized shares, 4,019,141 issued and outstanding

0

0

0

0

0

0

3

3

3

3

2

2

24

2

23

21

21

19

18

18

17

17

17

17

17

14

13

11

11

11

9

9

9

9

9

9

8

Additional paid-in capital

173,354

173,278

173,200

173,110

172,982

165,267

158,008

157,716

157,449

157,141

151,858

151,612

137,776

132,086

131,719

127,422

127,055

124,490

120,674

120,371

119,091

118,057

117,872

117,636

115,454

85,449

79,957

73,468

73,233

72,861

68,012

67,951

67,900

67,809

67,665

67,501

56,157

Stock subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accumulated other comprehensive income

-

2

7

7

-12

-17

-29

-64

-89

-56

-13

-25

-6

-6

-4

2

-1

-18

6

5

1

-33

-42

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accumulated deficit

-163,909

-163,322

-161,453

-159,494

-157,030

-154,687

-151,570

-146,231

-142,393

-140,318

-136,726

-135,688

-136,635

-115,024

-114,498

-111,631

-109,865

-105,716

-102,864

-98,838

-95,604

-91,332

-89,122

-87,216

-

-72,810

-

-

-

-

-

-

-

-

-

-

-

Accumulated other comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-2

Accumulated deficit during the development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

87,411

-

70,091

67,950

64,841

63,311

63,255

60,266

59,224

57,084

57,473

56,004

45,739

Treasury stock, 0 and 113,215 shares, at cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

128

128

128

128

128

128

28

28

28

28

28

28

28

28

28

28

28

28

28

Total Stockholders' Equity

9,445

9,957

11,755

13,623

15,939

10,562

6,411

11,423

14,969

16,768

15,120

15,901

1,129

17,058

17,239

15,814

17,209

18,775

17,706

21,428

23,377

26,580

28,597

30,308

28,032

12,625

9,851

5,502

8,375

9,533

4,737

7,665

8,657

10,706

10,172

11,478

10,395

Total Liabilities and Stockholders' Equity

11,552

12,968

14,980

17,677

19,425

16,042

13,874

18,235

22,554

28,287

24,590

28,093

19,582

21,043

22,741

20,530

25,557

24,805

23,074

27,369

30,481

33,533

36,453

39,244

41,121

19,556

16,073

11,074

13,352

14,919

7,977

9,758

11,709

13,689

18,688

21,875

16,216